SI3351539T1 - Kristalinični monohidratni kompleks 1-ciano-2-(4-ciklopropil- benzil)-4- (beta-d-glukopiranos-1-il)-benzena in L-prolina v kristalni vodi (1:1:1), postopki za njegovo pripravo in njegova uporaba kot inhibitor SGLT - Google Patents
Kristalinični monohidratni kompleks 1-ciano-2-(4-ciklopropil- benzil)-4- (beta-d-glukopiranos-1-il)-benzena in L-prolina v kristalni vodi (1:1:1), postopki za njegovo pripravo in njegova uporaba kot inhibitor SGLTInfo
- Publication number
- SI3351539T1 SI3351539T1 SI201332031T SI201332031T SI3351539T1 SI 3351539 T1 SI3351539 T1 SI 3351539T1 SI 201332031 T SI201332031 T SI 201332031T SI 201332031 T SI201332031 T SI 201332031T SI 3351539 T1 SI3351539 T1 SI 3351539T1
- Authority
- SI
- Slovenia
- Prior art keywords
- glucopyranos
- proline
- cyclopropyl
- cyano
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177944 | 2012-07-26 | ||
| EP18155079.9A EP3351539B1 (en) | 2012-07-26 | 2013-07-25 | Crystalline monohydrate complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(beta-d-glucopyranos-1-yl)-benzene and l-proline in crystal water (1:1:1), methods for its preparation and its use as an sglt inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3351539T1 true SI3351539T1 (sl) | 2023-03-31 |
Family
ID=48874313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201332031T SI3351539T1 (sl) | 2012-07-26 | 2013-07-25 | Kristalinični monohidratni kompleks 1-ciano-2-(4-ciklopropil- benzil)-4- (beta-d-glukopiranos-1-il)-benzena in L-prolina v kristalni vodi (1:1:1), postopki za njegovo pripravo in njegova uporaba kot inhibitor SGLT |
| SI201331237T SI2877460T1 (sl) | 2012-07-26 | 2013-07-25 | Kristalinični kompleks 1-ciano-2-(4-ciklopropil-benzil)-4- (beta-D-glukopiranoz-1-il)-benzena, postopki za njegovo pripravo in njegova uporaba za pripravo zdravil |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201331237T SI2877460T1 (sl) | 2012-07-26 | 2013-07-25 | Kristalinični kompleks 1-ciano-2-(4-ciklopropil-benzil)-4- (beta-D-glukopiranoz-1-il)-benzena, postopki za njegovo pripravo in njegova uporaba za pripravo zdravil |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9145434B2 (https=) |
| EP (3) | EP4166548A1 (https=) |
| JP (2) | JP6538556B2 (https=) |
| CN (2) | CN104470908A (https=) |
| AR (1) | AR091908A1 (https=) |
| AU (1) | AU2013294947B2 (https=) |
| BR (1) | BR112015001327B1 (https=) |
| CA (1) | CA2878698C (https=) |
| DK (2) | DK3351539T3 (https=) |
| EA (2) | EA025438B1 (https=) |
| ES (2) | ES2937665T3 (https=) |
| FI (1) | FI3351539T3 (https=) |
| HR (2) | HRP20181972T1 (https=) |
| HU (1) | HUE061450T2 (https=) |
| LT (1) | LT3351539T (https=) |
| MX (1) | MX357906B (https=) |
| PL (2) | PL3351539T3 (https=) |
| PT (2) | PT3351539T (https=) |
| RS (1) | RS63881B1 (https=) |
| SG (1) | SG11201500574QA (https=) |
| SI (2) | SI3351539T1 (https=) |
| TW (1) | TW201418275A (https=) |
| WO (1) | WO2014016381A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| PT2981269T (pt) | 2013-04-04 | 2023-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
| ES2969764T3 (es) * | 2013-12-17 | 2024-05-22 | Boehringer Ingelheim Vetmedica Gmbh | Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos |
| CN115671290A (zh) | 2014-01-23 | 2023-02-03 | 勃林格殷格翰动物保健有限公司 | 犬科动物中代谢紊乱的治疗 |
| WO2015150299A2 (en) | 2014-04-01 | 2015-10-08 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
| CN103965020B (zh) * | 2014-05-06 | 2015-09-09 | 启东东岳药业有限公司 | 制备5-碘-2-溴苄醇的方法 |
| WO2016046150A1 (en) * | 2014-09-25 | 2016-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| HUE052588T2 (hu) * | 2014-09-30 | 2021-05-28 | Jiangsu Hengrui Medicine Co | Az L-prolin/nátrium-glukóz kotranszporter 2 gátló kristály komplexének kristálya |
| CZ2015110A3 (cs) * | 2015-02-18 | 2016-08-31 | Zentiva, K.S. | Pevné formy empagliflozinu |
| KR102659761B1 (ko) | 2015-08-27 | 2024-04-24 | 베링거잉겔하임베트메디카게엠베하 | Sglt-2 억제제를 포함하는 액상 약제학적 조성물 |
| WO2017203457A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Solid state forms of empagliflozin |
| KR102226465B1 (ko) | 2016-05-28 | 2021-03-11 | 하이난 수안주 파마 코포레이션 리미티드 | 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형 |
| US11225500B2 (en) | 2017-12-19 | 2022-01-18 | Boehringer Ingelheim Vetmedica Gmbh | Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, L-proline and water |
| EP4064854A1 (en) | 2019-11-28 | 2022-10-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors in the drying-off of non-human mammals |
| AU2021222297B2 (en) | 2020-02-17 | 2026-01-22 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
| JP2024525981A (ja) | 2021-07-28 | 2024-07-12 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用 |
| JP2024527434A (ja) | 2021-07-28 | 2024-07-24 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用 |
| US20240269105A1 (en) | 2021-07-28 | 2024-08-15 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| AU2023277704A1 (en) | 2022-05-25 | 2024-12-05 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| EP4676494A1 (en) | 2023-03-06 | 2026-01-14 | Boehringer Ingelheim Vetmedica GmbH | Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
| WO2024223388A1 (en) | 2023-04-24 | 2024-10-31 | Boehringer Ingelheim Vetmedica Gmbh | Crystalline complexes between velagliflozin and selected co-crystal forming agents, methods for their preparation and the use thereof for preparing medicaments |
| KR20260019532A (ko) | 2023-05-24 | 2026-02-10 | 베링거잉겔하임베트메디카게엠베하 | 하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방 |
| US20240390317A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002254567B2 (en) * | 2001-04-11 | 2007-10-11 | Bristol-Myers Squibb Company | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| JP2006516257A (ja) * | 2003-01-03 | 2006-06-29 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ−アリールグルコシドｓｇｌｔ２阻害剤の製造法 |
| CN103030617A (zh) * | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| AU2006289093A1 (en) * | 2005-09-08 | 2007-03-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| AR059489A1 (es) * | 2006-02-15 | 2008-04-09 | Boehringer Ingelheim Vetmed | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| TW200904405A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| US20080287529A1 (en) * | 2007-05-18 | 2008-11-20 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
| CN101468976B (zh) * | 2007-12-27 | 2013-11-20 | 百时美施贵宝公司 | Sglt2抑制剂的晶体结构及其制备方法 |
| CN103910702A (zh) * | 2008-08-22 | 2014-07-09 | 泰拉科斯有限公司 | 制备sglt2抑制剂的方法 |
| AU2009286380B2 (en) | 2008-08-28 | 2011-09-15 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| WO2010048358A2 (en) | 2008-10-22 | 2010-04-29 | Auspex Pharmaceutical, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
| WO2011153712A1 (en) * | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| PT2981269T (pt) | 2013-04-04 | 2023-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
-
2013
- 2013-07-23 US US13/948,751 patent/US9145434B2/en active Active
- 2013-07-25 EA EA201500038A patent/EA025438B1/ru not_active IP Right Cessation
- 2013-07-25 EP EP22202153.7A patent/EP4166548A1/en active Pending
- 2013-07-25 AR ARP130102660A patent/AR091908A1/es unknown
- 2013-07-25 EP EP13740309.3A patent/EP2877460B1/en active Active
- 2013-07-25 ES ES18155079T patent/ES2937665T3/es active Active
- 2013-07-25 CA CA2878698A patent/CA2878698C/en active Active
- 2013-07-25 PL PL18155079.9T patent/PL3351539T3/pl unknown
- 2013-07-25 SI SI201332031T patent/SI3351539T1/sl unknown
- 2013-07-25 HR HRP20181972TT patent/HRP20181972T1/hr unknown
- 2013-07-25 CN CN201380037186.1A patent/CN104470908A/zh active Pending
- 2013-07-25 AU AU2013294947A patent/AU2013294947B2/en active Active
- 2013-07-25 JP JP2015523552A patent/JP6538556B2/ja active Active
- 2013-07-25 TW TW102126724A patent/TW201418275A/zh unknown
- 2013-07-25 MX MX2015000962A patent/MX357906B/es active IP Right Grant
- 2013-07-25 WO PCT/EP2013/065736 patent/WO2014016381A1/en not_active Ceased
- 2013-07-25 RS RS20230025A patent/RS63881B1/sr unknown
- 2013-07-25 PT PT181550799T patent/PT3351539T/pt unknown
- 2013-07-25 SI SI201331237T patent/SI2877460T1/sl unknown
- 2013-07-25 EP EP18155079.9A patent/EP3351539B1/en active Active
- 2013-07-25 HR HRP20230081TT patent/HRP20230081T1/hr unknown
- 2013-07-25 PT PT13740309T patent/PT2877460T/pt unknown
- 2013-07-25 DK DK18155079.9T patent/DK3351539T3/da active
- 2013-07-25 CN CN201810468431.9A patent/CN108774200A/zh active Pending
- 2013-07-25 ES ES13740309.3T patent/ES2694675T3/es active Active
- 2013-07-25 BR BR112015001327-9A patent/BR112015001327B1/pt active IP Right Grant
- 2013-07-25 SG SG11201500574QA patent/SG11201500574QA/en unknown
- 2013-07-25 PL PL13740309T patent/PL2877460T3/pl unknown
- 2013-07-25 EA EA201600506A patent/EA201600506A1/ru unknown
- 2013-07-25 LT LTEP18155079.9T patent/LT3351539T/lt unknown
- 2013-07-25 HU HUE18155079A patent/HUE061450T2/hu unknown
- 2013-07-25 DK DK13740309.3T patent/DK2877460T3/en active
-
2018
- 2018-05-08 JP JP2018089968A patent/JP2018135384A/ja active Pending
-
2022
- 2022-07-25 FI FIEP18155079.9T patent/FI3351539T3/fi active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE061450T2 (hu) | 1-ciano-2-(4-ciklopropil-benzil)-4-(béta-d-glükopiranosz-1-il)-benzol és L-prolin kristályos monohidrát komplexe kristályvízben (1:1:1), módszerek elõállítása és SGLT-inhibitorként való alkalmazása | |
| PL3110901T3 (pl) | Zastosowanie r-1233 w cieczowych urządzeniach chłodzących | |
| GB2524689B (en) | Cannabinoids for use in the treatment of neuropathic pain | |
| IL228967B (en) | Heterocyclic compounds as kinase inhibitors | |
| PT2667849T (pt) | Composição efervescente em forma sólida para utilização em aplicações vaginais para o tratamento de infeções vaginais | |
| IL231227A0 (en) | Compounds and preparations as kit inhibitors - c | |
| IL231226A0 (en) | Compounds and preparations as kit inhibitors - c | |
| IL232822B (en) | Furinone hydrochloride derivative, its crystals, preparations containing it and its uses | |
| PL2697218T3 (pl) | Sposób wytwarzania związków użytecznych, jako inhibitory SGLT2 | |
| IL250337A0 (en) | Preparations for use in the treatment of nephropathy and methods for their preparation | |
| IL225352A0 (en) | Process for the preparation of cdk-pan inhibitors according to formula (i) and intermediates in the preparation | |
| ZA201308541B (en) | Compounds for use in treatment of mucositis | |
| GB2490246B (en) | Use of compositions for growth and vigour in soybean | |
| GB2490250B (en) | Use of compositions for growth and vigour in cotton | |
| GB201113009D0 (en) | Improvements in and relating to fluid sample holders | |
| IL212725A (en) | Glycerol Preparation for Non-surgical Conjunctivochalysis | |
| GB201105928D0 (en) | Improvements in or relating to cold storage | |
| GB201117291D0 (en) | Improvements in or relating to cold storage | |
| GB201105285D0 (en) | Improvements in or relating to cold storage | |
| GB201105929D0 (en) | Improvements in or relating to cold storage | |
| GB201113134D0 (en) | Improvements in or relating to cold storage | |
| GB201105927D0 (en) | Improvements in or relating to cold storage | |
| GB201105923D0 (en) | Improvements in or relating to cold storage | |
| GB201101964D0 (en) | Improvements in or relating to cold storage | |
| GB201110660D0 (en) | Improvements in or relating to cold storage |